期刊文献+

多柔比星聚合物胶束制备、表征及其体外释药研究 被引量:1

Preparation, characterization and drug release property of doxorubicin-loaded polymeric micelles
下载PDF
导出
摘要 目的制备多柔比星的soluplus聚合物胶束,并对其进行体外评价。方法采用薄膜分散法-p H诱导法相结合制备多柔比星聚合物胶束;采用粒径测定仪、透射电镜、X-射线衍射(XRD)、差示扫描量热法(DSC)及红外光谱(FTIR)对其进行表征;采用HPLC法测定胶束的包封率和载药量;采用动态膜透析法考察载药胶束的体外释药特性。结果本研究制备的胶束呈球形或类球形,平均粒径为(67.57±2.9)nm,平均包封率为(77.81±4.03)%,平均载药量(10.15±1.56)%;XRD和DSC结果表明多柔比星以无定型状态或分子状态包载在聚合物胶束中;FTIR结果表明多柔比星分子中羟基和聚合物的羰基之间形成了氢键;体外释放结果表明多柔比星的soluplus聚合物胶束具有缓释作用。结论该胶束制备工艺简单,其粒径、包封率、载药量可控,具有缓释作用。 Objective To prepare doxorubicin-loaded soluplus polymeric micelles (ADM-PMs) and evaluate their quality. Methods The ADM-PMs were prepared by film dispersion method using an amphiphilic copolymer soluplus. The ADM-PMs were characterized by dynamic light scattering, transmission electron microscopy (TEM), X-ray diffraction (XRD), differential scanning calorimetry (DSC), and fourier transform-infrared spectra (FTIR). The release curve was determined by dialysis. Entrapment efficiency and drug loading were determined by HPLC. Results The ADM-PMs observed by TEM were spherical with a mean particle size of (67.57±2.9)nm, the encapsulation efficiency and drug loading of ADM-PMs were (77.81±4.03)% and (10.15±1.56)%. XRD and DSC determined that doxorubicin was in an amorphous or molecular form within the PMs. FTIR indicate that hydrogen bonds were formed between doxorubicin and polymer. Conclusion The ADM-PMs prepared had exhibited sustained release in vitro, and the particle size, encapsulation efficiency, and drug loading are controllable.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2015年第7期526-530,548,共6页 Chinese Journal of Antibiotics
基金 广东省科技计划项目(No.2014A020212296) 东莞市国际合作项目(No.2013508152013) 广东省青年创新项目(2014) 广东省大学生创新项目(No.1057113028 1057112043)
关键词 多柔比星 Soluplus 聚合物胶束 体外评价 Doxorubicin Soluplus Polymeric micelles In vitro evaluation
  • 相关文献

参考文献9

二级参考文献124

共引文献29

同被引文献27

  • 1Reintjes T.Solubility enhancement with BASF pharma polymers solubilizer compendium[M].Lampertheim Germany:Pharma Ingredients&Services,2011:67-72.
  • 2Vasconcelos T,Sarmento B,Costa P.Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs[J].Drug Discov Today,2007,12(23/24):1 068.
  • 3Chokshi RJ,Zia H,Sandhu HK,et al.Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution:pros and cons[J].Drug Deliv,2007,14(1):33.
  • 4Chokshi R,Zia H.Hot-melt extrusion technique:a review[J].Iran J Pharm Res,2004,3(1):3.
  • 5Chokshi RJ,Sandhu HK,Iyer RM,et al.Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution[J].J Pharm Sci,2005,94(11):2 463.
  • 6Liu JW,Zou MJ,Piao HY,et al.Characterization and pharmacokinetic study of aprepitant solid dispersions with soluplus?[J].Molecules,2015,20(6):11 345.
  • 7Lin Q,Fu Y,Li J,et al.A(polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability[J].Eur J Pharm Sci,2015,doi:10.1016/j.ejps.2015.08.018.
  • 8Lian XH,Dong JX,Zhang JJ,et al.Soluplus?based 9-nitrocamptothecin solid dispersion for peroral administration:preparation,characterization,in vitro and in vivo evaluation[J].Int J Pharm,2014,477(1/2):399.
  • 9Alshahrani SM,Lu W,Park JB,et al.Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus?and HPMCAS-HF[J].AAPS Pharm Sci Tech,2015,16(4):824.
  • 10Fule R,Dhamecha D,Maniruzzaman M,et al.Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form(ARLUMELT):evaluating amorphous state and in vivo performance[J].Int JPharm,2015,496(1):137.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部